{"organizations": [], "uuid": "02938541caeb7570d491aae29638f65a09336339", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-stratec-biomedical-to-propose-incr/brief-stratec-biomedical-to-propose-increased-dividend-of-eur-0-80-shr-idUSASO0003GO", "country": "US", "domain_rank": 408, "title": "BRIEF-STRATEC Biomedical To Propose Increased Dividend Of EUR 0.80/Shr", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-04-19T13:01:00.000+03:00", "replies_count": 0, "uuid": "02938541caeb7570d491aae29638f65a09336339"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-stratec-biomedical-to-propose-incr/brief-stratec-biomedical-to-propose-increased-dividend-of-eur-0-80-shr-idUSASO0003GO", "ord_in_thread": 0, "title": "BRIEF-STRATEC Biomedical To Propose Increased Dividend Of EUR 0.80/Shr", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "stratec biomedical ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "stratec", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - STRATEC Biomedical AG:\n* FY SALES ROSE 13.4 PERCENT TO 209.8 MILLION EUR * DIVIDEND 0.80 EURPER SHARE VERSUS 0.77 EURPER SHARE YEAR AGO\n* FY ADJUSTED EBIT RISES 10.1% TO EUR 35.5 MILLION IN 2017 (PREVIOUS YEAR: EUR 32.2 MILLION)\n* ADJUSTED CONSOLIDATED EARNINGS 10.4% HIGHER IN 2017 AT EUR 27.9 MILLION\n* OUTLOOK 2018: FURTHER GROWTH FORECAST * EXPECTS ADJUSTED EBIT MARGIN FOR FISCAL 2018 IN LINE WITH PREVIOUS YEARâ€™S FIGURE OF AROUND 17%\n* OUTLOOK 2018: AT LEAST MID-SINGLE-DIGIT ORGANIC SALES GROWTH\n* EXPECTS TO GENERATE MOST OF SALES GROWTH PLANNED FOR 2018 IN SECOND HALF OF FINANCIAL YEAR\n* TO PROPOSE TRANSFORMATION OF STRATEC BIOMEDICAL INTO EUROPEAN COMPANY KNOWN AS STRATEC SE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T13:01:00.000+03:00", "crawled": "2018-04-20T12:11:26.004+03:00", "highlightTitle": ""}